{
    "nct_id": "NCT05675930",
    "official_title": "A Multi-Center, Phase II, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Photobiomodulation for the Treatment of Oral Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (the LIGHT Trial)",
    "inclusion_criteria": "* Allo-HCT recipients\n* Age ≥ 4 years-old\n* Oral cGvHD with NIH-modified OMRS score ≥ 3 who have failed ≥ 1 line of therapy, including topical corticosteroids..\n* No change in systemic immunosuppressive therapy (type or intensity level) within 2 weeks prior to enrollment.\n* If a patient is currently using another oral topical treatment for mouth lesions/symptoms, patient must be stable on this treatment for ≥2 weeks prior to study enrollment. Patient may continue same topical dose/frequency during the study period.\nHealthy volunteers allowed\nMust have minimum age of 4 Years",
    "exclusion_criteria": "* Presence of an active uncontrolled infection. Subjects with a controlled infection receiving definitive therapy for 48 hours prior to enrollment are eligible.\n* Personal history of mucosal head and neck cancer in the past 5 years.\n* Pregnant or breastfeeding.\n* The subject or guardian is unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.\n* Any serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.",
    "miscellaneous_criteria": ""
}